Feli M Walther1, Mark J Allan2, Rainer K A Roepke3. 1. Merck Animal Health, 2 Giralda Farms, Madison, NJ, USA. feli.walther@merck.com. 2. MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany. mark.allan@msd.de. 3. MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany. rainer.roepke@msd.de.
Abstract
BACKGROUND: Fluralaner is a novel systemic ectoparasiticide for dogs providing immediate and persistent flea, tick and mite control after a single oral dose. Ivermectin has been used in dogs for heartworm prevention and at off label doses for mite and worm infestations. Ivermectin pharmacokinetics can be influenced by substances affecting the p-glycoprotein transporter, potentially increasing the risk of ivermectin neurotoxicity. This study investigated ivermectin blood plasma pharmacokinetics following concurrent administration with fluralaner. FINDINGS: Ten Beagle dogs each received a single oral administration of either 56 mg fluralaner (Bravecto™), 0.3 mg ivermectin or 56 mg fluralaner plus 0.3 mg ivermectin/kg body weight. Blood plasma samples were collected at multiple post-treatment time points over a 12-week period for fluralaner and ivermectin plasma concentration analysis. Ivermectin blood plasma concentration profile and pharmacokinetic parameters Cmax, tmax, AUC∞ and t½ were similar in dogs administered ivermectin only and in dogs administered ivermectin concurrently with fluralaner, and the same was true for fluralaner pharmacokinetic parameters. CONCLUSIONS: Concurrent administration of fluralaner and ivermectin does not alter the pharmacokinetics of either compound. Based on the plasma pharmacokinetic profile and the clinical observations, there is no evident interaction between fluralaner and ivermectin, and co-administration does not increase the risk of ivermectin associated neurotoxicity.
BACKGROUND:Fluralaner is a novel systemic ectoparasiticide for dogs providing immediate and persistent flea, tick and mite control after a single oral dose. Ivermectin has been used in dogs for heartworm prevention and at off label doses for mite and worm infestations. Ivermectin pharmacokinetics can be influenced by substances affecting the p-glycoprotein transporter, potentially increasing the risk of ivermectinneurotoxicity. This study investigated ivermectin blood plasma pharmacokinetics following concurrent administration with fluralaner. FINDINGS: Ten Beagle dogs each received a single oral administration of either 56 mg fluralaner (Bravecto™), 0.3 mg ivermectin or 56 mg fluralaner plus 0.3 mg ivermectin/kg body weight. Blood plasma samples were collected at multiple post-treatment time points over a 12-week period for fluralaner and ivermectin plasma concentration analysis. Ivermectin blood plasma concentration profile and pharmacokinetic parameters Cmax, tmax, AUC∞ and t½ were similar in dogs administered ivermectin only and in dogs administered ivermectin concurrently with fluralaner, and the same was true for fluralaner pharmacokinetic parameters. CONCLUSIONS: Concurrent administration of fluralaner and ivermectin does not alter the pharmacokinetics of either compound. Based on the plasma pharmacokinetic profile and the clinical observations, there is no evident interaction between fluralaner and ivermectin, and co-administration does not increase the risk of ivermectin associated neurotoxicity.
Authors: Tara E Paterson; Richard E Halliwell; Paul J Fields; Marta Lanza Louw; Jakobus P Louw; Geoff S Ball; Rhonda D Pinckney; John S McKibben Journal: Vet Dermatol Date: 2009-10 Impact factor: 1.589
Authors: Marie Miglianico; Maarten Eldering; Hannah Slater; Neil Ferguson; Pauline Ambrose; Rosemary S Lees; Karin M J Koolen; Katerina Pruzinova; Magdalena Jancarova; Petr Volf; Constantianus J M Koenraadt; Hans-Peter Duerr; Graham Trevitt; Baiyuan Yang; Arnab K Chatterjee; John Wisler; Angelika Sturm; Teun Bousema; Robert W Sauerwein; Peter G Schultz; Matthew S Tremblay; Koen J Dechering Journal: Proc Natl Acad Sci U S A Date: 2018-07-02 Impact factor: 11.205
Authors: Vicky Wilkinson; Kotaro Takano; David Nichols; Alynn Martin; Roz Holme; David Phalen; Kate Mounsey; Michael Charleston; Alexandre Kreiss; Ruth Pye; Elizabeth Browne; Christina Næsborg-Nielsen; Shane A Richards; Scott Carver Journal: Parasit Vectors Date: 2021-01-06 Impact factor: 3.876